1065481-27-7

Basic information

• Product Name: (R)-1-(2-Chloro-8-fluoroquinolin-3-yl)ethanol
• Synonyms: (R)-1-(2-Chloro-8-fluoroquinolin-3-yl)ethanol
• CAS NO: 1065481-27-7
• Molecular Formula: C11H9ClFNO
• Molecular Weight: 225.6466632
• Mol File: 1065481-27-7.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (R)-1-(2-Chloro-8-fluoroquinolin-3-yl)ethanol(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(2-Chloro-8-fluoroquinolin-3-yl)ethanol(1065481-27-7)
• EPA Substance Registry System: (R)-1-(2-Chloro-8-fluoroquinolin-3-yl)ethanol(1065481-27-7)

Safety Data

• Hazardous Substances Data: 1065481-27-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-(2-Chloro-8-fluoroquinolin-3-yl)ethanol is used as a potential active pharmaceutical ingredient for the development of new drugs. Its unique structure, including the quinoline ring and halogen substituents, may contribute to its interaction with biological targets, such as enzymes or receptors, leading to potential therapeutic effects.
Used in Medicinal Chemistry Research:
(R)-1-(2-Chloro-8-fluoroquinolin-3-yl)ethanol serves as a valuable compound in medicinal chemistry research for the design and synthesis of novel drug candidates. Its chirality and specific functional groups can be exploited to investigate the structure-activity relationship (SAR) of potential drugs, optimizing their potency, selectivity, and pharmacokinetic properties.
Used in Chiral Chemistry:
(R)-1-(2-Chloro-8-fluoroquinolin-3-yl)ethanol is utilized in chiral chemistry to study the effects of stereochemistry on the biological activity and pharmacological properties of compounds. As a single enantiomer, it can provide insights into the role of stereoselectivity in drug action and help develop enantiomerically pure drugs with improved safety and efficacy profiles.
Used in Drug Synthesis:
(R)-1-(2-Chloro-8-fluoroquinolin-3-yl)ethanol can be employed as a key intermediate or building block in the synthesis of more complex drug molecules. Its versatile structure allows for further functionalization and modification, enabling the creation of diverse drug candidates with potential applications in various therapeutic areas.

Upstream product

• 348-54-9 2-Fluoroaniline 
• 1065481-25-5 1-(2-chloro-8-fluoroquinolin-3-yl)ethanol 
• 124467-23-8 2-chloro-8-fluoroquinoline 
• 71738-83-5 8-fluoroquinolin-2(1H)-one 
• 1065481-24-4 (2E)-N-(2-fluorophenyl)-3-phenylprop-2-enamide 
• 1065481-26-6 1-(2-chloro-8-fluoroquinolin-3-yl)ethanone 

Downstream Products

• 1065481-28-8 (S)-3-(1-azidoethyl)-2-chloro-8-fluoro-quinoline 
• 1464832-35-6 2-((1S)-1-(8-fluoro-2-(2-(methylthio)phenyl)quinolin-3-yl)ethyl)isoindoline-1,3-dione 
• 1464832-37-8 2-((1S)-1-(8-fluoro-2-(2-(methylsulfonyl)phenyl)-3-quinolinyl)ethyl)-1H-isoindole-1,3(2H)-dione 
• 1464832-39-0 (1S)-1-(8-fluoro-2-(2-(methylsulfonyl)phenyl)-3-quinolinyl)ethanamine 
• 1464832-30-1 4-amino-6-(((1S)-1-(8-fluoro-2-(2-(methyl-sulfonyl)phenyl)-3-quinolinyl)ethyl)amino)-5-pyrimidinecarbonitrile 
• 1065478-86-5 N-((S)-1-(8-fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethyl)-9H-purin-6-amine 
• 1065481-30-2 (1S)-1-(8-fluoro-2-(3-fluorophenyl)quinolin-3-yl)ethanamine 
• 1065481-29-9 3-((S)-1-azidoethyl)-8-fluoro-2-(3-fluorophenyl)quinoline 

Relevant articles and documents

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity, The present invention also enables methods for treating cancers that are mediated, dependent on or associated with p110δ activity, including but not restricted to leukemias, such as Acute Myeloid leukaemia (AML) Myelo-dysplastic syndrome (MDS) myelo-proliferative diseases (MPD) Chronic Myeloid Leukemia (CML) T-cell Acute Lymphoblastic leukaemia (T-ALL) B-cell Acute Lymphoblastic leukaemia (B-ALL) Non Hodgkins Lymphoma (NHL) B-cell lymphoma and solid tumors, such as breast cancer.

HETEROCYCLIC COMPOUNDS AND THEIR USES

Substituted bicyclic heteroaryls and compositions containing them, for the treatment of general inflammation, arthritis, rheumatic diseases, osteoarthritis, inflammatory bowel disorders, inflammatory eye disorders, inflammatory or unstable bladder disorders, psoriasis, skin complaints with inflammatory components, chronic inflammatory conditions, including but not restricted to autoimmune diseases such as systemic lupus erythematosis (SLE), myestenia gravis, rheumatoid arthritis, acute disseminated encephalomyelitis, idiopathic thrombocytopenic purpura, multiples sclerosis, Sjoegren's syndrome and autoimmune hemolytic anemia, allergic conditions including all forms of hypersensitivity. The present invention also enables methods for treating cancers that are mediated, dependent on, or associated with p110 activity, including but not restricted to leukemias, such as acute myeloid leukaemia (AML), myelo-dysplastic syndrome (MDS), myelo-proliferative diseases (MPD), chronic myeloid leukemia (CML), T-cell acute lymphoblastic leukaemia (T-ALL), B-cell acute lymphoblastic leukaemia (B-ALL), non Hodgkins lymphoma (NHL), B-cell lymphoma and solid tumors, such as breast cancer.